Pediatric Urology and Regenerative Medicine Research Center, Section of Tissue Engineering and Stem Cells Therapy, Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran, No. 62, Dr. Gharib's Street, Keshavarz Boulevard, 1419433151, Tehran, Iran.
Adv Exp Med Biol. 2021;1345:35-46. doi: 10.1007/978-3-030-82735-9_4.
Since lung tissue is not able to be reconstructed after substantial injury, lung transplantation often is the only alternative for treatment. Antibiotic-resistant organisms that remain in donor lungs causing infection in the immunosuppressed recipient are among the complications following transplantation. Development of strategies for whole lung regeneration is a pleasing choice particularly in patients with end-stage lung diseases. Reconstruction of lung tissue in vitro for transplantation received increased attention which could deal with the shortage of donor organs. Recent advancements in the field of tissue engineering and regenerative medicine have paved the road for beneficial alternative therapies. Our group has extensive experience with regard to the structure of the lung tissue, which makes us to our decision to continue with the preparation of lung, with the aim of developing a new ECM scaffold. Herein, we aim to review the state-of-art and the tissue engineering and regenerative medicine technology highlighting the major achievements toward the production of a bioengineered lung obtained decellularization and recellularization techniques. We have strong hopes that recent developments in the engineering of lung will lead to similar breakthroughs in the engineering of distal lung components in the future.
由于肺组织在受到实质性损伤后无法重建，肺移植通常是治疗的唯一选择。在移植后，导致免疫抑制受者感染的抗生素耐药生物体仍然存在于供体肺中，这是并发症之一。开发全肺再生策略是一个令人满意的选择，特别是在患有终末期肺病的患者中。体外肺组织重建用于移植受到了越来越多的关注，这可以解决供体器官短缺的问题。组织工程和再生医学领域的最新进展为有益的替代疗法铺平了道路。我们的团队在肺组织结构方面拥有丰富的经验，这使我们决定继续准备肺，以开发新的 ECM 支架。在这里，我们旨在回顾组织工程和再生医学技术的最新进展，突出强调通过脱细胞和再细胞化技术生产生物工程肺的主要成就。我们强烈希望，肺工程的最新进展将导致未来在远端肺成分工程方面取得类似的突破。
